Suven Life Sciences Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 23.85 million compared to INR 26.11 million a year ago. Revenue was INR 66.68 million compared to INR 82.13 million a year ago. Net loss was INR 265.41 million compared to INR 276.45 million a year ago. Basic loss per share from continuing operations was INR 1.22 compared to INR 1.17 a year ago. Diluted loss per share from continuing operations was INR 1.22 compared to INR 1.17 a year ago.
For the full year, sales was INR 116.93 million compared to INR 135.39 million a year ago. Revenue was INR 328.23 million compared to INR 219.88 million a year ago. Net loss was INR 1,050.76 million compared to INR 1,182.68 million a year ago. Basic loss per share from continuing operations was INR 4.82 compared to INR 6.63 a year ago. Diluted loss per share from continuing operations was INR 4.82 compared to INR 6.63 a year ago.